利拉鲁肽治疗2型糖尿病肥胖患者心功能不全的疗效观察

摘要

Objective To observe the curative ef ect of liraglutide treatmentseeking obese type 2 diabetes mel itus patients with cardiac insuf iciency.Methods 60 cases of obese type 2 diabetic patients in our hospital in 2013 January ~2014 June in our hospital, were randomly divided into observation group and control group. The observation group based on the original hypoglycemic drugs with liraglutide treatment, the control group using the original treatment of hypoglycemic drugs. Comparison of two methods in the treatment of patients before and after treatment,fasting blood glucose, 2H postprandial blood glucose, 2H postprandialinsulin and C peptide, glycosylated hemoglobin, blood pressure, weight,blood lipid. Results After the treatment, the observation group and the control group were FBG, 2hBG, BMI, HbAlc etc. have improved significantly, there are obvious dif erences and compared with those before the treatment, but the observation group and the control grouphad no significant dif erence between the two groups, P>0.05. In BMI,systolic pressure, men and women, waist and hip circumference, the treatment ef ect of the observation group was bet er than the control group, compared the dif erences, P< 0.05. After treatment, the observation group and the control group of patients with left ventricularejection fraction were lower than before treatment significantly improved,but the patients in the observation group is bet er than that of the control group patients, the two groups had dif erence,P<0.05, there was statistical significance. Conclusion With liraglutide treatment based onhypoglycemic drugs on the original, reducing the weight and blood pressure and blood lipid of patients, improved the function of islet beta cel s, improve the heart function of patients, is a new treatment option forpatients with type 2 diabetes mel itus heart dysfunction.%目的：探寻利拉鲁肽治疗2型糖尿病肥胖患者心功能不全的疗效观察。方法选取我院2013年1月~2014年6月来我院就诊的60例2型糖尿病肥胖患者，随机分为观察组和对照组。观察组在原有的降糖药物的基础上加上利拉鲁肽进行治疗，对照组采用原有的降糖药物进行治疗。比较两种方法治疗患者治疗前后的空腹血糖、餐后2H血糖、餐后2H胰岛素及 c肽、体重、糖化血红蛋白、血压、血脂等指标。结果经治疗后，观察组和对照组患者的 FBG、2hBG、BMI、HbAlc等方面了有了明显的改善，和治疗前对比有明显差异性，但是观察组和对照组两组之间未见明显差异，P＞0.05。在BMI、收缩压，男女性腰围和臀围上，观察组的治疗效果明显优于对照组，比较有差异，P＜0.05。治疗后观察组和对照组患者的左室射血分数均较治疗之前有明显的改善，但观察组患者的改善要优于对照组患，两组比较有差异性，P＜0.05，有统计学意义。结论在原有的降糖药物的基础上加上利拉鲁肽治疗，降低了患者的体重和血压血脂，改善了胰岛β细胞功能，改善了患者心功能，是2型糖尿病肥胖患者心功能不全的治疗新选择。